NSC 23766, a cell-permeable compound, is a reversible and specific inhibitor of Rac GTPase. Its primary application lies in the field of cancer treatment.

NSC 23766 (100?μM) treatment effectively inhibits polar body emission in a dose-dependent manner. NSC 23766 (200 μM) increases the percentage of morphologically abnormal spindles of oocytes. In NSC 23766-treated oocytes, the p-MAPK protein expression is significantly decreased[2]. NSC23766 (50?μM) plus 100?ng/mL Jagged1, GDF9 and BMP15, reduces the number of germLine cell cysts and increases the number of primordial follicles[3]. NSC23766 significantly inhibits GTP-Rac1 activity and phosphorylation of Rac1-PAK, ERKs and p38 MAPK in the spinal dorsal horn neurons[4].

NSC23766, administered intraperitoneally at a dosage of 2.5 mg/kg/day, markedly delays the onset of spontaneous diabetes in NOD mice without notably influencing their growth, as measured by body weights. Furthermore, this compound significantly elevates the expression levels of Rac1 and CHOP, an endoplasmic reticulum (ER) stress marker, in the islets of NOD mice[1].